Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Slagle Financial LLC

Slagle Financial LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 91.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,336 shares of the biopharmaceutical company's stock after selling 25,788 shares during the quarter. Slagle Financial LLC's holdings in Gilead Sciences were worth $262,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Brighton Jones LLC increased its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $339,000. Personal CFO Solutions LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $207,000. Johnson Investment Counsel Inc. increased its holdings in shares of Gilead Sciences by 10.3% in the 4th quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock valued at $1,536,000 after acquiring an additional 1,549 shares during the period. Finally, Independent Advisor Alliance increased its holdings in shares of Gilead Sciences by 35.4% in the 4th quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock valued at $2,968,000 after acquiring an additional 8,398 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $111.38.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider owned 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock valued at $6,340,745 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 4.3%

NASDAQ:GILD traded down $4.90 on Friday, reaching $109.64. The stock had a trading volume of 6,115,020 shares, compared to its average volume of 7,700,134. The company has a market cap of $136.38 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 0.73 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm's fifty day moving average is $107.62 and its two-hundred day moving average is $104.50. Gilead Sciences, Inc. has a 12-month low of $68.14 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.32) EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.